Full Text View
Tabular View
No Study Results Posted
Related Studies
Framing Messages for Smoking Cessation With Bupropion - 6
This study is ongoing, but not recruiting participants.
Study NCT00104598   Information provided by National Institute on Drug Abuse (NIDA)
First Received: March 1, 2005   Last Updated: November 3, 2005   History of Changes

March 1, 2005
November 3, 2005
September 2000
 
  • Medication compliance
  • Smoking Cessation
Same as current
Complete list of historical versions of study NCT00104598 on ClinicalTrials.gov Archive Site
 
 
 
Framing Messages for Smoking Cessation With Bupropion - 6
Framing Messages for Smoking Cessation With Buproprion

This is a randomized study of message framing in individuals beginning a smoking cessation program utilizing bupropion SR and brief counseling, videos, and pamphlets.

 
 
Interventional
Treatment, Parallel Assignment
Tobacco Use Disorder
Drug: Bupropion
 
 

*   Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
 
Active, not recruiting
252
 
 

Exclusion Criteria:

  • Pregnant or nursing women, or women of child-bearing potential who are not using an adequate method of contraception
  • Psychiatric illnesses requiring psychotropic medications (i.e., psychosis, major depression, mania), or the presence of suicidality or homocidality
  • Current use of nicotine replacement therapies (i.e., nicotine patch, gum, or lozenges, nasal spray, or inhaler), bupropion (Zyban, Wellbutrin), or marijuana or current participation in another smoking cessation treatment
  • Presence of unstable medical conditions (i.e., cardiac, hepatic, renal disease, diabetes mellitus) that would make a trial of bupropion SR hazardous
  • Have taken monoamine oxidase inhibitors or metoprolol succinate within the past six weeks
  • History of anorexia nervosa or bulimia
  • Previous hypersensitivity to bupropion
  • History of alcohol or other drug dependence in the past one year
  • History of seizure disorder of any etiology (i.e., brain tumor, traumatic brain injury, substance-induced seizures, etc.)
  • Any finding that in the view of the principal investigator would compromise the subject's ability to fulfill the protocol visit schedule and visit requirements or put the subject at risk
  • Sharing home or work environment with current or past participant
  • No couples or participants who see each other every day
Both
18 Years to 70 Years
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00104598
 
NIDA-13334-6, P50-13334-6
National Institute on Drug Abuse (NIDA)
 
Principal Investigator: Stephanie O'Malley, Ph.D. Substance Abuse Treatment Unit
National Institute on Drug Abuse (NIDA)
February 2005

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP